APO Research
Talk to an analyst

APO RESEARCH · REPORT

Benign Prostatic Hyperplasia (BPH) Drugs

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

Selected research

Market Analysis & Forecast

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis and Forecast 2026-2032

30 December 2025192 pages

Choose your research edition.

Industry ResearchBenign Prostatic Hyperplasia (BPH) Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Benign Prostatic Hyperplasia (BPH) Drugs Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Benign Prostatic Hyperplasia (BPH) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Benign Prostatic Hyperplasia (BPH) Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.

This report presents an overview of global market for Benign Prostatic Hyperplasia (BPH) Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

Read the full market overview

This report researches the key producers of Benign Prostatic Hyperplasia (BPH) Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Benign Prostatic Hyperplasia (BPH) Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Benign Prostatic Hyperplasia (BPH) Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Benign Prostatic Hyperplasia (BPH) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Benign Prostatic Hyperplasia (BPH) Drugs sales, projected growth trends, production technology, application and end-user industry.

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Company

Eli Lilly

GlaxoSmithKline

Astellas Pharma

Sanofi

Pfizer

Abbott

Allergan

TEVA

Mylan

Novartis

Merck

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type

Alpha-Blocker

Phosphodiesterase Type-5 Inhibitors

Others

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application

Hospitals

Drugstores

Others

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Benign Prostatic Hyperplasia (BPH) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Benign Prostatic Hyperplasia (BPH) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Benign Prostatic Hyperplasia (BPH) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Benign Prostatic Hyperplasia (BPH) Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Benign Prostatic Hyperplasia (BPH) Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Alpha-Blocker Major Manufacturers Table 3. Phosphodiesterase Type-5 Inhibitors Major Manufacturers Table 4. Others Major Manufacturers Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospitals Major Manufacturers Table 7. Drugstores Major Manufacturers Table 8. Others Major Manufacturers Table 9. Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends Table 10. Benign Prostatic Hyperplasia (BPH) Drugs Industry Drivers Table 11. Benign Prostatic Hyperplasia (BPH) Drugs Industry Opportunities and Challenges Table 12. Benign Prostatic Hyperplasia (BPH) Drugs Industry Restraints Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2021-2026) Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2027-2032) Table 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (M Units) Table 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2021-2026) & (M Units) Table 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2027-2032) & (M Units) Table 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2021-2026) Table 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2027-2032) Table 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2021-2026) Table 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers, Product Type & Application Table 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Benign Prostatic Hyperplasia (BPH) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2021-2026) Table 38. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2027-2032) Table 39. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type 2021 VS 2025 VS 2032 (M Units) Table 40. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (M Units) Table 41. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2027-2032) & (M Units) Table 42. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2021-2026) Table 43. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2027-2032) Table 44. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2021-2026) & (US$/Unit) Table 45. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2027-2032) & (US$/Unit) Table 46. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2021-2026) Table 50. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2027-2032) Table 51. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application 2021 VS 2025 VS 2032 (M Units) Table 52. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (M Units) Table 53. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2027-2032) & (M Units) Table 54. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2021-2026) Table 55. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2027-2032) Table 56. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2021-2026) & (US$/Unit) Table 57. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2027-2032) & (US$/Unit) Table 58. Eli Lilly Company Information Table 59. Eli Lilly Business Overview Table 60. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 62. Eli Lilly Recent Development Table 63. GlaxoSmithKline Company Information Table 64. GlaxoSmithKline Business Overview Table 65. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 67. GlaxoSmithKline Recent Development Table 68. Astellas Pharma Company Information Table 69. Astellas Pharma Business Overview Table 70. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 72. Astellas Pharma Recent Development Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 77. Sanofi Recent Development Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 82. Pfizer Recent Development Table 83. Abbott Company Information Table 84. Abbott Business Overview Table 85. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 87. Abbott Recent Development Table 88. Allergan Company Information Table 89. Allergan Business Overview Table 90. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 92. Allergan Recent Development Table 93. TEVA Company Information Table 94. TEVA Business Overview Table 95. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 97. TEVA Recent Development Table 98. Mylan Company Information Table 99. Mylan Business Overview Table 100. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 102. Mylan Recent Development Table 103. Novartis Company Information Table 104. Novartis Business Overview Table 105. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 107. Novartis Recent Development Table 108. Merck Company Information Table 109. Merck Business Overview Table 110. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 112. Merck Recent Development Table 113. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 114. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 115. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (M Units) Table 116. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2027-2032) & (M Units) Table 117. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 118. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 119. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 120. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 121. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (M Units) Table 122. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2027-2032) & (M Units) Table 123. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 124. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 125. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 127. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 128. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021 VS 2025 VS 2032) & (M Units) Table 129. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026) & (M Units) Table 130. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2027-2032) & (M Units) Table 131. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 132. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 133. United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 134. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 135. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 136. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 137. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 138. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (M Units) Table 139. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2027-2032) & (M Units) Table 140. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 141. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 142. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 143. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 144. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (M Units) Table 145. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2027-2032) & (M Units) Table 146. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 147. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 148. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 149. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 150. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 151. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021 VS 2025 VS 2032) & (M Units) Table 152. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026) & (M Units) Table 153. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2027-2032) & (M Units) Table 154. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 155. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 156. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 157. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 158. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 159. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 160. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 161. Spain Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 162. Netherlands Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 163. Switzerland Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 164. Sweden Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 165. Poland Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 166. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 167. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 168. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (M Units) Table 169. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2027-2032) & (M Units) Table 170. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 171. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 172. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 173. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 174. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (M Units) Table 175. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2027-2032) & (M Units) Table 176. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 177. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 178. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 179. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 180. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (M Units) Table 181. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2027-2032) & (M Units) Table 182. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 183. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 184. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 185. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 186. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (M Units) Table 187. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2027-2032) & (M Units) Table 188. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 189. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 190. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 191. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 192. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 193. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021 VS 2025 VS 2032) & (M Units) Table 194. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026) & (M Units) Table 195. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2027-2032) & (M Units) Table 196. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 197. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 198. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 199. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 200. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 201. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 202. Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 203. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 204. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 205. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 206. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (M Units) Table 207. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2027-2032) & (M Units) Table 208. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 209. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 210. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 211. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 212. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (M Units) Table 213. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2027-2032) & (M Units) Table 214. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 215. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 216. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 217. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 218. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 219. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021 VS 2025 VS 2032) & (M Units) Table 220. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026) & (M Units) Table 221. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2027-2032) & (M Units) Table 222. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 223. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 224. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 225. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 226. Chile Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 227. Colombia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 228. Peru Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 229. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 230. Israel Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 231. UAE Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 232. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 233. Iran Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 234. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Table 235. Key Raw Materials Table 236. Raw Materials Key Suppliers Table 237. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List Table 238. Benign Prostatic Hyperplasia (BPH) Drugs Customers List Table 239. Research Programs/Design for This Report Table 240. Authors List of This Report Table 241. Secondary Sources Table 242. Primary Sources List of Figures Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Image Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Alpha-Blocker Image Figure 5. Phosphodiesterase Type-5 Inhibitors Image Figure 6. Others Image Figure 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospitals Image Figure 10. Drugstores Image Figure 11. Others Image Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2032) & (US$ Million) Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2021-2032) Figure 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (2021-2032) & (M Units) Figure 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2021 VS 2025 VS 2032 (M Units) Figure 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY (2021-2032) & (M Units) Figure 21. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY (2021-2032) & (M Units) Figure 22. China Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY (2021-2032) & (M Units) Figure 23. Asia (Excluding China) Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY (2021-2032) & (M Units) Figure 24. South America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY (2021-2032) & (M Units) Figure 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2021-2032) Figure 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021 VS 2025 VS 2032) & (M Units) Figure 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2021-2032) Figure 34. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2021-2032) Figure 37. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021 VS 2025 VS 2032) & (M Units) Figure 38. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2021-2032) Figure 40. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2021-2032) Figure 41. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2021-2032) Figure 42. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2021-2032) Figure 43. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2021-2032) Figure 44. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Country (2021-2032) Figure 45. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Country (2021-2032) Figure 46. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2021-2032) Figure 47. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2021-2032) Figure 48. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2021-2032) Figure 49. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2021-2032) Figure 50. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Country (2021-2032) Figure 51. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Country (2021-2032) Figure 52. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2021-2032) Figure 53. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2021-2032) Figure 54. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2021-2032) Figure 55. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2021-2032) Figure 56. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2021-2032) Figure 57. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2021-2032) Figure 58. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2021-2032) Figure 59. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2021-2032) Figure 60. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Country (2021-2032) Figure 61. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Country (2021-2032) Figure 62. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2021-2032) Figure 63. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2021-2032) Figure 64. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2021-2032) Figure 65. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2021-2032) Figure 66. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Country (2021-2032) Figure 67. SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Country (2021-2032) Figure 68. Benign Prostatic Hyperplasia (BPH) Drugs Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Alpha-Blocker
  • Phosphodiesterase Type-5 Inhibitors
  • Others
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Eli Lilly
  • GlaxoSmithKline
  • Astellas Pharma
  • Sanofi
  • Pfizer
  • Abbott
  • Allergan
  • TEVA
  • Mylan
  • Novartis
  • Merck

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Benign Prostatic Hyperplasia (BPH) Drugs Market by Type
  3. 1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Alpha-Blocker
  5. 1.2.3 Phosphodiesterase Type-5 Inhibitors
  6. 1.2.4 Others
  7. 1.3 Benign Prostatic Hyperplasia (BPH) Drugs Market by Application
  8. 1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals
  10. 1.3.3 Drugstores
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Benign Prostatic Hyperplasia (BPH) Drugs Market Dynamics
  1. 2.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
  2. 2.2 Benign Prostatic Hyperplasia (BPH) Drugs Industry Drivers
  3. 2.3 Benign Prostatic Hyperplasia (BPH) Drugs Industry Opportunities and Challenges
  4. 2.4 Benign Prostatic Hyperplasia (BPH) Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region
  3. 3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
  9. 3.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers
  2. 4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers
  6. 4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market CR5 and HHI
  16. 4.8.2 2025 Benign Prostatic Hyperplasia (BPH) Drugs Tier 1, Tier 2, and Tier 3
5 Benign Prostatic Hyperplasia (BPH) Drugs Market by Type
  1. 5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type
  2. 5.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
  6. 5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2032) & (M Units)
  8. 5.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type
6 Benign Prostatic Hyperplasia (BPH) Drugs Market by Application
  1. 6.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application
  2. 6.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
  6. 6.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2032) & (M Units)
  8. 6.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application
7 Company Profiles
  1. 7.1 Eli Lilly
  2. 7.1.1 Eli Lilly Company Information
  3. 7.1.2 Eli Lilly Business Overview
  4. 7.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  6. 7.1.5 Eli Lilly Recent Developments
  7. 7.2 GlaxoSmithKline
  8. 7.2.1 GlaxoSmithKline Company Information
  9. 7.2.2 GlaxoSmithKline Business Overview
  10. 7.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  12. 7.2.5 GlaxoSmithKline Recent Developments
  13. 7.3 Astellas Pharma
  14. 7.3.1 Astellas Pharma Company Information
  15. 7.3.2 Astellas Pharma Business Overview
  16. 7.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  18. 7.3.5 Astellas Pharma Recent Developments
  19. 7.4 Sanofi
  20. 7.4.1 Sanofi Company Information
  21. 7.4.2 Sanofi Business Overview
  22. 7.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  24. 7.4.5 Sanofi Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Abbott
  32. 7.6.1 Abbott Company Information
  33. 7.6.2 Abbott Business Overview
  34. 7.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  36. 7.6.5 Abbott Recent Developments
  37. 7.7 Allergan
  38. 7.7.1 Allergan Company Information
  39. 7.7.2 Allergan Business Overview
  40. 7.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  42. 7.7.5 Allergan Recent Developments
  43. 7.8 TEVA
  44. 7.8.1 TEVA Company Information
  45. 7.8.2 TEVA Business Overview
  46. 7.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  48. 7.8.5 TEVA Recent Developments
  49. 7.9 Mylan
  50. 7.9.1 Mylan Company Information
  51. 7.9.2 Mylan Business Overview
  52. 7.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  54. 7.9.5 Mylan Recent Developments
  55. 7.10 Novartis
  56. 7.10.1 Novartis Company Information
  57. 7.10.2 Novartis Business Overview
  58. 7.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  60. 7.10.5 Novartis Recent Developments
  61. 7.11 Merck
  62. 7.11.1 Merck Company Information
  63. 7.11.2 Merck Business Overview
  64. 7.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  66. 7.11.5 Merck Recent Developments
8 North America
  1. 8.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
  2. 8.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2021-2032)
  5. 8.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
  6. 8.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2021-2032)
  9. 8.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
  10. 8.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
  2. 9.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2021-2032)
  5. 9.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
  6. 9.2.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2021-2032)
  9. 9.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
  10. 9.3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
  2. 10.1.1 China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2021-2032)
  5. 10.2 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
  6. 10.2.1 China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
  2. 11.1.1 Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2021-2032)
  5. 11.2 Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
  6. 11.2.1 Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2021-2032)
  9. 11.3 Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
  10. 11.3.1 Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Benign Prostatic Hyperplasia (BPH) Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
  2. 12.1.1 SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
  6. 12.2.1 SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
  10. 12.3.1 SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Benign Prostatic Hyperplasia (BPH) Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Benign Prostatic Hyperplasia (BPH) Drugs Value Chain Analysis
  2. 13.1.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process
  6. 13.2 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
  9. 13.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst